Drug Profile
Research programme: antifibrinolytic therapeutics - PDS Biotechnology
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Edge Therapeutics
- Developer PDS Biotechnology Corporation
- Class Antifibrinolytics
- Mechanism of Action Antifibrinolytic agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Surgical blood loss
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Surgical-blood-loss in USA (Topical)
- 18 Mar 2019 PDS Biotechnology Corporation merged with Edge Therapeutics to form PDS Biotechnology Corporation
- 22 Dec 2015 Early research in Surgical blood loss in USA (Topical)